UroGen Pharma (NASDAQ:URGN – Get Free Report) will issue its quarterly earnings data before the market opens on Thursday, March 14th. Analysts expect the company to announce earnings of ($0.67) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link. UroGen Pharma Trading Down […]
NervGen Pharma Corp. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has been recognized by the TSX Venture Exchange as a.
NervGen Pharma Corp. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that it has granted incentive stock.
NervGen Pharma Corp : NervGen Pharma Grants Stock Options finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.